Empagmet 12.5/850mg
Empagliflozin 12.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
MFDS item code 202302734 · Approved 2023.09.12
Improvement of glycemic control in adults with type 2 diabetes mellitus
This medication is used in combination of empagliflozin and metformin to improve blood sugar control in adult patients with type 2 diabetes. It is administered as an adjunct to diet and exercise, suitable for patients whose blood sugar is not adequately controlled. Particularly for patients with type 2 diabetes who have cardiovascular diseases, clinical trial information regarding the occurrence of cardiovascular events should be referenced. This medication improves blood sugar control and effectively aids in diabetes management.
The recommended dose of this medicine is 1 tablet twice daily. The dose should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25 mg and metformin 2000 mg. ⦁ For patients who are unable to achieve adequate glycemic control with metformin alone or in combination with other medicines such as insulin, the recommended dose is empagliflozin 5 mg twice daily (total daily dose 10 mg) and their current dose of metformin. If empagliflozin 10 mg (total daily dose) is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg (total daily dose). ⦁ Patients switching to this medicine from combination therapy with empagliflozin (total daily dose 10 mg or 25 mg) and metformin should receive their current doses of empagliflozin and metformin. When this medicine is used concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, 4. Adverse Reactions and 6. Interactions). This medicine should be taken with meals to reduce gastrointestinal adverse reactions associated with metformin. If you miss a dose of this medicine, take it as soon as you remember. However, do not take a double dose at one time; if this happens, skip the missed dose. Special populations Patients with renal impairment No dose adjustment is required in patients with mild renal impairment. Because this medicine contains metformin, it may be used with dose adjustment in patients with an estimated glomerular filtration rate (eGFR) of 45-59 ml/min/1.73m2 or a CrCl of 45-59 ml/min who have no other conditions that may increase the risk of lactic acidosis. Since the starting dose of metformin in these patients is 500 mg or 850 mg once daily, treatment should be initiated with the individual single-ingredient products of empagliflozin and metformin. The maximum daily dose of metformin hydrochloride that may be administered with this medicine is 1000 mg, which may be given as 500 mg twice daily. Renal function should be carefully monitored every 3-6 months (see Precautions for Use, 3. Patients Requiring Caution, item 1)). If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately (see Precautions for Use, 2. Patients Who Must Not Take This Medicine, item 2)). Elderly patients For patients 75 years of age or older, renal function and the risk of volume depletion should be considered.
This medication helps control blood sugar. However, it may cause a rare side effect called severe lactic acidosis, and if this symptom occurs, immediate medical attention is necessary. When used in conjunction with other diabetes treatments, severe hypoglycemic symptoms may occasionally occur, requiring caution. Patients with severely reduced kidney function, acute kidney issues, heart failure, or acute myocardial infarction should not use this medication. The use of this medication should be temporarily discontinued before and after tests using radiographic contrast agents, and it should only be resumed after confirming normal kidney function. Patients scheduled for surgery should discontinue this medication 48 hours before surgery and resume only after kidney function has recovered post-surgery. Patients with liver dysfunction or excessive alcohol consumption may have an increased risk of lactic acidosis while on this medication. Women who are pregnant, possibly pregnant, or breastfeeding are advised not to take this medication. During treatment, regular monitoring of kidney function and blood tests should be conducted to check for irregularities. Hypoglycemic symptoms may arise; hence, blood glucose should be closely monitored, especially when taken with insulin or sulfonylurea medications. Urinary tract or genital infections may occur, so if related symptoms arise, immediate consultation with a physician is recommended. Due to the risk of fluid loss, if symptoms of dehydration, diarrhea, or vomiting occur, medical guidance should be sought. If symptoms such as fever, genital pain, swelling, or rash occur during treatment, immediate notification to medical personnel is required, and if severe, medication discontinuation should be considered. This medication is not recommended for children under 18 years of age, and those over 75 years may require dose adjustments and regular testing due to the risk of decreased kidney function. In case of overdose, the risk of lactic acidosis increases; thus, the prescribed dosage should be strictly followed, and if unusual symptoms occur, one should go to the hospital immediately. This medication should be kept out of reach of children and stored in its original container for safety.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to prevent air or moisture from entering. It is best stored at room temperature, between 1 degree and 30 degrees Celsius.
Pink-tinged white, bilaterally convex oval film-coated tablets
10 tablets/box (10 tablets/PTP x 1), 60 tablets/box (10 tablets/PTP x 6), 60 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Empagliflozin 12.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 12.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 12.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 12.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Donggu Bio Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.